Latest news

Hide mandatory notifications of trade

Notice of results for the fourth quarter and full year ended 31 December 2015

(Oslo, Norway, 8 February 2016) Bionor Pharma ASA (OSE:BIONOR) will report its financial results for the fourth quarter and full year ended 31 December 2015 on 12 February 2016 at no later than 11:30 CET.

Bionor will host a conference call for analysts and investors 12 February 2016 at 13:00 CET at which David H. Solomon, President and CEO, and Jens Krøis, CFO, will provide an update of the business. To attend the conference, please use the participant code 1059479.

Norway:                     +47 2316 2771
Denmark:                   +45 32 71 16 58
United Kingdom:         +44 20 3427 1905
USA:                          +1 646 254 3365
Sweden:                     +46 8 5033 6538

A presentation will be available on the company’s website prior to the call. A webcast of the conference call will be available during and after the event. Link to webcast:

Further information
Jørgen Fischer Ravn, VP Investor Relations & Communications, +45 20 30 39 03,

About Bionor
Bionor Pharma is a Norwegian biopharmaceutical company focused on advancing its proprietary therapeutic vaccine Vacc-4x in combination with other medicines toward a functional HIV cure. The company believes it has first mover potential based on clinical results to date and early adoption of now recognized clinical strategy. In December 2015, Bionor announced that the HIV ’Shock & Kill’ trial REDUC with Vacc-4x and romidepsin successfully met its primary endpoint by reducing latent HIV reservoir and further demonstrated control of viral load. Bionor is currently planning BIOSKILL, a proof-of-concept Phase II trial, which may lead to a major value inflection point and partnering opportunities. Bionor currently retains full ownership rights to Vacc-4x, i.e., the upside potential from partnering or licensing remains with the company. Bionor is based in Oslo, Norway, and also has offices in Copenhagen, Denmark and New York, USA. Bionor is listed on Oslo Børs (OSE:BIONOR). More information about Bionor is available at

Announcement as PDF.